This study is a first-in-human (FIH), randomized, double-blind, placebo-controlled study of PMG1016 in healthy adult participants. It aims to investigate the safety, tolerability, PK, and immunogenicity of PMG1016 administered via IV infusion.
Cohort 1: Healthy participants receiving single doses of PMG1016 Dose 1 or placebo.
Cohort 2: Healthy participants receiving single doses of PMG1016 Dose 2 or placebo.
Cohort 3: Healthy participants receiving single doses of PMG1016 Dose 3 or placebo.
Cohort 4: Healthy participants receiving single doses of PMG1016 Dose 4 or placebo.